This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theisen, M.
Right arrow Articles by Druilhe, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theisen, M.
Right arrow Articles by Druilhe, P.

 Previous Article  |  Next Article 

Infection and Immunity, September 2001, p. 5223-5229, Vol. 69, No. 9
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.9.5223-5229.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Selection of Glutamate-Rich Protein Long Synthetic Peptides for Vaccine Development: Antigenicity and Relationship with Clinical Protection and Immunogenicity

Michael Theisen,1,* Daniel Dodoo,2 Aissatou Toure-Balde,3 Soe Soe,4,5 Giampietro Corradin,6 Kwadwo K. Koram,2 Jørgen A. L. Kurtzhals,2,7,8 Lars Hviid,7,8 Thor Theander,7,8 Bartholomew Akanmori,2 Mohamadou Ndiaye,3 and Pierre Druilhe4

Department of Clinical Biochemistry, Statens Serum Institut,1 Centre for Medical Parasitology at Department of Infectious Diseases, Copenhagen University Hospital,7 and Institute for Medical Microbiology and Immunology, University of Copenhagen,8 Copenhagen, Denmark; Immunology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana2; Institut Pasteur, Dakar, Senegal3; Laboratoire de Parasitologie Médicale, Institut Pasteur, Paris, France4; Department of Medical Research, Yangon, Myanmar5; and Institute of Biochemistry, Lausanne, Switzerland6

Received 8 January 2001/Returned for modification 15 March 2001/Accepted 24 May 2001

Antibodies against three long synthetic peptides (LSPs) derived from the glutamate-rich protein (GLURP) of Plasmodium falciparum were analyzed in three cohorts from Liberia, Ghana, and Senegal. Two overlapping LSPs, LR67 and LR68, are derived from the relatively conserved N-terminal nonrepeat region (R0), and the third, LR70, is derived from the R2 repeat region. A high prevalence of antibody responses to each LSP was observed in all three areas of endemic infection. Levels of cytophilic immunoglobulin G (IgG) antibodies against both GLURP regions were significantly correlated with protection from clinical P. falciparum malaria. Protected children from the Ghana cohort possessed predominantly IgG1 antibodies against the nonrepeat epitope and IgG3 antibodies against the repeat epitope. T-cell proliferation responses, studied in the cohort from Senegal, revealed that T-helper-cell epitopes were confined to the nonrepeat region. When used as immunogens, the LR67 and LR68 peptides elicited strong IgG responses in outbred mice and LR67 also induced antibodies in mice of different H-2 haplotypes, confirming the presence of T-helper-cell epitopes in these constructs. Mouse antipeptide antisera recognized parasite proteins as determined by immunofluorescence and immunoblotting. This indicates that synthetic peptides derived from relatively conserved epitopes of GLURP might serve as useful immunogens for vaccination against P. falciparum malaria.

* Corresponding author. Mailing address: Department of Clinical Biochemistry, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. Phone: (45) 32683779. Fax: (45) 32683228. E-mail: mth{at}ssi.dk.

Infection and Immunity, September 2001, p. 5223-5229, Vol. 69, No. 9
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.9.5223-5229.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lundquist, R., Nielsen, L. K., Jafarshad, A., SoeSoe, D., Christensen, L. H., Druilhe, P., Dziegiel, M. H. (2006). Human Recombinant Antibodies against Plasmodium falciparum Merozoite Surface Protein 3 Cloned from Peripheral Blood Leukocytes of Individuals with Immunity to Malaria Demonstrate Antiparasitic Properties.. Infect. Immun. 74: 3222-3231 [Abstract] [Full Text]  
  • BOUSEMA, J. T., ROEFFEN, W., VAN DER KOLK, M., DE VLAS, S. J., VAN DE VEGTE-BOLMER, M., BANGS, M. J., TEELEN, K., KURNIAWAN, L., MAGUIRE, J. D., BAIRD, J. K., SAUERWEIN, R. W. (2006). RAPID ONSET OF TRANSMISSION-REDUCING ANTIBODIES IN JAVANESE MIGRANTS EXPOSED TO MALARIA IN PAPUA, INDONESIA.. Am J Trop Med Hyg 74: 425-431 [Abstract] [Full Text]  
  • Carvalho, L. J. M., Alves, F. A., Bianco, C. Jr., Oliveira, S. G., Zanini, G. M., Soe, S., Druilhe, P., Theisen, M., Muniz, J. A. P. C., Daniel-Ribeiro, C. T. (2005). Immunization of Saimiri sciureus Monkeys with a Recombinant Hybrid Protein Derived from the Plasmodium falciparum Antigen Glutamate-Rich Protein and Merozoite Surface Protein 3 Can Induce Partial Protection with Freund and Montanide ISA720 Adjuvants. CVI 12: 242-248 [Abstract] [Full Text]  
  • Cavanagh, D. R., Dodoo, D., Hviid, L., Kurtzhals, J. A. L., Theander, T. G., Akanmori, B. D., Polley, S., Conway, D. J., Koram, K., McBride, J. S. (2004). Antibodies to the N-Terminal Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Associated with Protection against Clinical Malaria. Infect. Immun. 72: 6492-6502 [Abstract] [Full Text]  
  • Mahanty, S., Saul, A., Miller, L. H. (2003). Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. 206: 3781-3788 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»